FDA Launches New Adverse Event Look-Up Tool
The FDA has launched the FDA Adverse Event Monitoring System (AEMS), a new unified platform designed to streamline the analysis of adverse event reports and increase safety data transparency for regulated products.
This platform affects manufacturers of all FDA-regulated products, as well as pharmacovigilance, regulatory affairs, and post-market safety teams responsible for monitoring and reporting adverse events.
The consolidation of safety data into a unified platform suggests an increased FDA capability for signal detection and cross-product analysis. This modernization may lead to more frequent or rapid safety inquiries as the agency facilitates broader public and internal access to adverse event trends. Regulatory teams should anticipate that this transparency could heighten scrutiny of post-market safety profiles by external stakeholders.
Regulatory and pharmacovigilance teams should audit internal adverse event data against the new AEMS platform to identify potential reporting discrepancies. Quality units may need to update post-market surveillance procedures to incorporate this tool into routine safety monitoring and signal detection workflows.
FDA launched a new unified platform for analyzing adverse event reports. This platform — called the FDA Adverse Event Monitoring System (AEMS) — represents a major achievement in the agency’s mission to modernize and provide radical transparency into the safety of regulated products.
Open in openFDA / FDA.gov